Adenosine biology remains central to neonatal hypoxic-ischemic brain injury
A short letter in JAMA Pediatrics returns to a question that has shadowed neonatal neurology for decades: whether manipulating adenosine signaling could help protect the brain after perinatal asphyxia at term. The writer responds to the Viewpoint by Robertson and colleagues with a reminder from mid-1990s laboratory work, when adenosine was already being considered as a biologically plausible mediator of neuroprotection after hypoxic-ischemic encephalopathy.
The argument is not built on marketing language or therapeutic optimism. It is built on physiology. During oxygen deprivation, the fetal and newborn brain shifts into a stress response in which adenosine can dampen excitotoxic injury, reduce neuronal overactivation, and limit the downstream damage that follows severe hypoxia. In that framework, adenosine is not a casual bystander. It is part of the protective circuitry the brain recruits when oxygen delivery collapses.
One sentence in the letter captures the long arc of this idea: a colleague had emphasized, on the basis of laboratory work, that adenosine might matter for neuroprotection after term perinatal asphyxia because of its ability to reduce excitotoxicity. The message has aged well. In the injured neonatal brain, excitotoxicity is one of the most destructive immediate processes, driven by excessive stimulation that amplifies cell death and worsens the final neurologic burden.
Caffeine sits awkwardly in that story.
Why a methylxanthine is biologically difficult to defend
Caffeine is best known in neonatal care for its established role in apnea of prematurity, not for rescue after term brain injury. Its pharmacology makes the caution understandable. By antagonizing adenosine receptors, caffeine can interfere with a pathway that may be useful during hypoxic stress. In other words, a drug that is helpful when the clinical problem is immature respiratory drive may be poorly matched to a condition in which adenosine signaling could be part of endogenous neuroprotection.
That biological tension is the point of the letter. The writer is not merely rejecting a therapy; the writer is reminding readers why the mechanism matters. A treatment built to blunt adenosine effects may be a poor fit when the desired effect is preservation of adenosine-mediated defense against injury. In the setting of term asphyxia, the question is not whether a drug is familiar in neonatology. The question is whether its molecular target aligns with the brain’s acute response to oxygen deprivation.
The letter also references earlier work by Peter Marro and colleagues, which supported the same general direction of thinking. The details of that study are not expanded in the brief correspondence, but its inclusion signals continuity across the field: adenosine has repeatedly surfaced as a candidate mediator in the biology of fetal and neonatal hypoxia. The concept was reinforced by prior animal-model work examining the fetal development of enzymes involved in adenosine metabolism during fetal hypoxia. Those developmental data mattered because they linked enzyme maturation, oxygen stress, and brain vulnerability in a single pathway.
What fetal hypoxia taught the field about timing and vulnerability
The fetal brain is not simply a smaller version of the adult brain. Enzymatic pathways, receptor expression, and metabolic reserve differ in ways that alter the response to injury. The animal-model work cited in the letter emphasized the importance of adenosine in the fetal brain during hypoxic stress, which is exactly where neonatal translational thinking tends to begin: with a mechanism that is plausible in animals, developmentally coherent in the fetus, and clinically relevant in a term newborn after a catastrophic intrapartum event.
In that context, adenosine is attractive because it links cellular stress to protection. During hypoxia, the brain’s own chemistry shifts toward limiting damage, and adenosine appears to be one of the signals that helps do so. Blocking that signal may blunt a native defense system at the very moment it is needed most. For clinicians, that makes the caution around caffeine more than a theoretical objection. It becomes a bedside concern about whether a routine neonatal drug could conflict with the biology of acute brain injury.
The letter does not present a trial, a dosing comparison, or a clinical endpoint. It does something narrower and, in some ways, more durable: it reanchors the discussion in mechanism. In neonatal neurology, mechanism is often the first filter for plausibility, especially when the margin for harm is narrow and the neurologic cost of failed protection is high.
A reminder for neonatal neuroprotection research
The lasting value of this brief correspondence lies in its restraint. It does not claim that adenosine-based strategies are ready for clinical deployment, and it does not convert animal data into a treatment recommendation. Instead, it preserves a biologic warning that remains relevant whenever a proposed intervention touches the adenosine system in a hypoxic newborn.
For hypoxic-ischemic encephalopathy, that warning is straightforward: not every neonatal drug with central nervous system effects belongs in the same injury state. A therapy that makes sense for apnea of prematurity may be mechanistically misaligned with perinatal asphyxia at term, where endogenous adenosine may be trying to limit excitotoxicity rather than causing the problem.
The correspondence leaves readers with a narrow but useful clinical principle: before using caffeine, or any adenosine-active intervention, in the setting of neonatal brain injury, the mechanism has to be right for the disease biology. In this case, the biology favors caution, and the letter leaves no room for casual extrapolation from one neonatal indication to another.